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optimal health care through the elicitation of physicians’ and
pharmacists’ preferences to health care, even in the particular
context of hemophilia management.
PBR9
ASSESSING HEALTH-RELATED QUALITY OF LIFE IN
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OBJECTIVES: Inadequate treatment of haemophiliacs leads to
high rate of chronic arthropathy, high number of transfusion-
transmitted diseases and poor social integration. The objectives
of our study were to measure HRQOL and utilities in
haemophilia patients and to evaluate the inﬂuence of
haemophilia severity, patient’s age and socio-professional status
on HRQOL and utilities. METHODS: We used SF-36 and EQ-
5D questionnaires in 100 haemophilia patients with severe (66),
moderate (18) and mild form (16 cases), registered and treated
in Haemophilia Center Timisoara. Mean age of the patients was
23.14 years. We considered two age groups: 16–24 years (60
patients) and 25–34 years (40 patients). Seventeen of the
haemophiliacs were schoolboys, 13-university students, 19-
employees and 51 were handicapped with social support.
RESULTS: Compared with Romanian general population norms
(available only for SF-36 questionnaire) HRQOL is affected in
haemophilia patients in both age groups, although age was not
a strong predictor of HRQOL or utilities. Haemophilia severity
was found to have a strong inﬂuence on HRQOL and utilities.
Regarding the socio-professional status, handicapped with social
support had the lowest HRQOL scores and utilities values.
CONCLUSIONS: Our results conﬁrm the need to develop
special long-term national programs in order to improve
haemophilia treatment, to reduce the number and the severity of
complications, to offer a better social integration of the patients
and to improve their quality of life.
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OBJECTIVES: To establish which characteristics patients con-
sider important in prophylaxis, and if cost of treatment could
inﬂuence their preferences. METHODS: A focus group identi-
ﬁed ﬁve characteristics: type of product (plasma-derived vs.
recombinant), infusions frequency, hemorrhages frequency, pos-
sibility to do vigorous physical activities, possibility to do usual
activities. Patients gave their opinion rating each characteristic
from zero (not important) to 100 (very important). Scenarios
describing hypothetical treatment modalities were administered
to patients who were asked to chose one for each couple pre-
sented. The characteristic “cost”, expressed as increase in health
care taxes, was then added in each scenario and patients were
invited to make again their choices. RESULTS: Fifteen people,
13 adult patients and 2 parents, were enrolled. The characteris-
tic considered most important was “usual activities” (median =
95), followed by “hemorrhages frequency” (86), “infusions fre-
quency” (81), “type of product” (76), “vigorous physical activ-
ities” (69) and ﬁnally “cost” (50). Almost all patients did not
suggest other important characteristics. Eleven patients (73%)
changed at least one choice when “cost” was present. CON-
CLUSIONS: This pilot study allowed us to identify aspects con-
sidered by hemophilia patients as important in prophylaxis.
These results will help us to design a Conjoint Analysis aimed at
evaluating utilities and monetary value of these aspects.
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OBJECTIVES: We evaluated Health-Related Quality of Life
(HR-QoL) in hemophilia people with inhibitors and investigated
if QoL is associated to patients’ clinical status. METHODS: The
COCIS (Cost Of Care of Inhibitors) study was a longitudinal
study involving 52 hemophiliacs (median age 35, 15–64) with
inhibitors, 98% high responders, sequentially enrolled at 11
Italian Hemophilia Care Centers. Information on demographics,
clinical status, health-care resources consumption was prospec-
tively collected. QoL was investigated by means of the generic
instruments EQ-5D and SF-36. RESULTS: With the EQ-proﬁle
the majority of patients reported some/moderate problems 
in domains “pain/discomfort” (72%), “mobility” (66%) and
“usual activities” (54%). Around one third declared some/mod-
erate problems with “anxiety/depression” (34%) and “self-care”
(32%). No more than 6% of patients reported severe problems
in any of the domains. The EQ-Visual Analogue Scale (VAS),
measuring the global health state perception, was normally dis-
tributed, with a median value of 66 (30–95). The SF-Mental
Component Summary (MCS) had a median value of 52.8
(15.5–68.1), while the SF-Physical Component Summary (PCS)
had a median value of 35.2 (15.2–55.0). A strong association
was found between orthopedic status and global HR-QoL (EQ-
VAS, Pearson’s r = 0.56, p < 0.01). In particular, the physical
component of HR-QoL was the most inﬂuenced by the patients’
orthopedic status (Physical Component Summary, Pearson’s r =
-0.359, p < 0.01). Other clinical parameters, in particular
inhibitor titers and bleeding frequency, were not associated with
patients’ HR-QoL. CONCLUSIONS: Modern health care strate-
gies aimed at treating or, better, at preventing hemophilic
arthropathy should be considered to improve quality of life in
inhibitor patients.
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OBJECTIVES: The aim of this work is to evaluate inﬂuence of
clinical and socio-demographic characteristics on the strength of
preferences towards each characteristic. METHODS: We ana-
lyzed data originated by CONAN database from 178 patients.
Patients were asked to make choices between variables of
replacement therapy such as perceived viral safety, risk of
inhibitor development, infusion frequency on prophylaxis, phar-
maceutical dosage form, way of distribution and price.
RESULTS: The value of each characteristic was indicated by its
monetary value: the monetary value for perceived viral safety
was greater for moderate (2547€) compared to severe hemo-
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philiacs (1810€) and was greater for patients in recombinant
treatment (2421€) to plasma derived (1001€). Compared to
moderate hemophiliacs, severe hemophiliacs placed a higher
value on the decrease in the risk of developing inhibitors (1033€
vs. 518€) and on the infusion frequency (706€ vs. 144€). The
employment status played an important role on monetary values
attributed to way of distribution: employed patients placed a
higher monetary value to “home delivery” (1495€) and “ofﬁce
pharmacy distribution” (2589€) compared to self-employed
patients (541€ and 89€, respectively) and to unemployed patients
(1002€ and 928€). CONCLUSIONS: We demonstrate that clin-
ical and socio-demographic characteristics inﬂuenced patients’
preferences. One of the practical utilities of conjoint analysis
consist in the capability of target different group with different
characteristics that consequently require different therapeutic
decisions. This allow to plan optimal hemophilia care.
DIABETES
DIABETES—Clinical Outcomes Studies
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OBJECTIVES: Diabetes mellitus (DM) is a cluster of metabolic
disorders, requiring chronic care. Cockram et al found that 1) a
majority (62%) of those diagnosed with type 2 DM did not have
access to programs providing patient education in Hong Kong,
and 2) an alarming proportion (~50%) of patients with diabetes
were not sufﬁciently informed about the risk of complications.
The purpose of this study is to investigate the relationship of DM
patients’ medical knowledge and adherence to medical advice to
their glycaemic control. METHODS: The study adopted the
prospective, observational study design. Patients with DM who
were followed up at the specialist outpatient clinic at the Princes
of Wales Hospital were recruited. Two sets of Chinese question-
naires published in Yung et al were used to assess patients’ 1)
knowledge of DM, adherence to medical advice (maximum score
= 10) and 2) knowledge of signs and symptoms of hypoglycaemic
attacks (maximum score = 13). Demographic information, gly-
cosylated haemoglobin A1C (HbA1C) levels and any previous
history of hypoglycaemic attacks were recorded. Pearson
product-moment correlation coefﬁcients were used to identify
the associations between knowledge, adherence to medical
advice and glycaemic control (SPSS, 11.5.1, Chicago). RESULTS:
A total of 178 medical records were screened and 119 patients
(53% male; age: 62.2 ± 11.7 years old; mean duration of DM:
6.8 years) were recruited. The mean HbA1C level was 7.64 ±
1.55 %. The mean scores for the 2 questionnaires were 5.30 ±
1.88 and 4.29 ± 3.07 respectively. The correlation coefﬁcients
between the scores and the HbA1C levels were 0.024 and -0.061
respectively (P > 0.05). Patients with previous history of hypo-
glycaemic attach scored signiﬁcantly higher in the second 
questionnaire (mean difference = -1.784, P = 0.003). CON-
CLUSIONS: Patients’ knowledge on DM and adherence to
medical advice had no association with glycaemic control.
DIABETES
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OBJECTIVES: Several diabetes models have been developed to
determine cost-effectiveness of therapy, some of which predict
multiple complications. In these models, quality-adjusted life
years (QALY’s) have been estimated by multiplying health utility
scores for individual complications, largely due to a lack of
empirical data. This study evaluated the impact of this assump-
tion using empirical utility values to model multiple complica-
tions in patients with type-2 diabetes. METHODS: This study
used the Cardiff Stochastic Simulation Cost-Utility Model (Dia-
bForecaster), which follows 10,000 newly diagnosed patients
with type-2 diabetes over 20 years. We included the most reli-
able estimates of diabetes-related health utility scores using data
from the Health Outcomes Data Repository (HODaR). The
model employed baseline risk proﬁles used by Eastman. Utility
scores were incorporated either multiplicatively (utility values for
multiple complications were calculated by multiplying utility
values for individual complications), or empirically (direct
empirical data were used for patients with 1 and 2 complications
and average utility decrements were used for subjects with ≥3
complications). QALY estimates were obtained assuming com-
prehensive (HbA1c = 7.2%) or standard care (HbA1c = 10%).
The discount rate for beneﬁt was 1.5%. RESULTS: There were
1965 (8.6%) patients with type-2 diabetes in HODaR. The
overall mean utility for diabetic patients was 0.564 (SD ± 0.319)
for males and 0.508 (SD ± 0.358) for females. This ranged from
0.716 (SD ± 0.267) in outpatients with no reported complica-
tions to 0.490 (SD ± 0.353) in those with ≥3 vascular events.
Over 20 years, predicted QALYs ranged from a mean of 8.3
(multiplicative) to 8.9 per patient (empirical) assuming compre-
hensive care. Under standard care, the QALYS ranged from 6.8
(multiplicative) to 7.9 per patient (empirical). CONCLUSIONS:
The model predicted variations >1 QALY depending on how the
utility estimates were incorporated. The method chosen to value
health utility for multiple complications in diabetes models can
affect cost-effectiveness estimates of diabetes-related therapies.
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OBJECTIVES: A recent clinical trial demonstrated non-inferior-
ity in HbA1c and hypoglycaemic events with insulin detemir
(IDet) compared to NPH in a basal/bolus regimen. Mean body
weight in the IDet group increased less than the NPH group (0.4
Kg vs. 1.3Kg respectively p = 0.017). The aim of this analysis
was to use a validated diabetes model to link these short-term
outcomes to long-term complication rates and associated UK
health care costs, and to calculate the cost-effectiveness of treat-
ment with IDet in type-2 diabetes. METHODS: A validated,
non-proprietorial model, The Core Diabetes Model, was used to
predict: long-term complications; improvements in Life Years
